Literature DB >> 20447229

Ineligibility and refusal to participate in randomised trials of treatments for drug dependence.

Hans O Melberg1, Keith Humphreys.   

Abstract

ISSUES: The aim of this study is to examine the extent to which drug-dependent patients are ineligible for or unwilling to participate in randomised clinical trials. This is important because unrepresentative sample selection is a potentially important problem for randomised trials in the drug dependence field and little is known about the magnitude of the problem. APPROACH: A total of 98 clinical trials were drawn for analysis from a systematic review of the drug dependence treatment literature. KEY
FINDINGS: The trials reviewed excluded an average of 29% of potential subjects as ineligible; a further 29% of the eligible subjects were unwilling to participate. Trials comparing widely different treatments had a higher proportion of ineligible and unwilling subjects than did studies comparing more similar treatments. Experiments with large samples enrolled a smaller proportion of patients from their sampling pool than did experiments with small samples. IMPLICATIONS: Drug-dependent trial subjects are a minority of all drug patients seen in real-world clinical practice. It is necessary to improve the reporting of these potential problems in randomised trials. Systematic reviews of the literature ought to use this information to distinguish reliable from less reliable findings.
CONCLUSION: Unrepresentative sample selection is a serious problem for randomised trials in the drug dependence field.

Entities:  

Mesh:

Year:  2010        PMID: 20447229     DOI: 10.1111/j.1465-3362.2009.00096.x

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  11 in total

1.  Patterns of prescription opioid abuse and comorbidity in an aging treatment population.

Authors:  Theodore J Cicero; Hilary L Surratt; Steven Kurtz; M S Ellis; James A Inciardi
Journal:  J Subst Abuse Treat       Date:  2011-08-09

2.  Representativeness of patients enrolled in influential clinical trials: a comparison of substance dependence with other medical disorders.

Authors:  Keith Humphreys; Natalya C Maisel; Janet C Blodgett; John W Finney
Journal:  J Stud Alcohol Drugs       Date:  2013-11       Impact factor: 2.582

3.  Generalizability of pharmacological and psychotherapy clinical trial results for borderline personality disorder to community samples.

Authors:  Nicolas Hoertel; Saioa López; Shuai Wang; Ana González-Pinto; Frédéric Limosin; Carlos Blanco
Journal:  Personal Disord       Date:  2015-01

4.  Multicentre study for validation of the French addictovigilance network reports assessment tool.

Authors:  Caroline Victorri-Vigneau; Jean Benoit Hardouin; Morgane Rousselet; Marie Gerardin; Marylène Guerlais; Morgane Guillou; Marie Bronnec; Véronique Sébille; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

Review 5.  Virtual recruitment and participant engagement for substance use research during a pandemic.

Authors:  Carolin C Hoeflich; Anna Wang; Ayodeji Otufowora; Linda B Cottler; Catherine W Striley
Journal:  Curr Opin Psychiatry       Date:  2022-06-09       Impact factor: 4.787

6.  Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010.

Authors:  Keith Humphreys; Natalya C Maisel; Janet C Blodgett; Ingrid L Fuh; John W Finney
Journal:  JAMA Intern Med       Date:  2013-06-10       Impact factor: 21.873

7.  Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications.

Authors:  Alexandra Venegas; Lindsay R Meredith; Ziva D Cooper; Brandon Towns; Lara A Ray
Journal:  Alcohol Alcohol       Date:  2020-06-25       Impact factor: 3.913

8.  Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center.

Authors:  Brian Rush; Olivia Marcus; Sara García; Anja Loizaga-Velder; Gabriel Loewinger; Ariane Spitalier; Fernando Mendive
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

9.  Prevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: results from a national epidemiological sample.

Authors:  Nicolas Hoertel; Yann Le Strat; Frédéric Limosin; Caroline Dubertret; Philip Gorwood
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  How Should We Study Residential Recovery Homes?

Authors:  Douglas L Polcin
Journal:  Ther Communities       Date:  2015-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.